
Home » GLAXO SIGNS ANTIGEN DEAL TO BOOST CANCER VACCINES
GLAXO SIGNS ANTIGEN DEAL TO BOOST CANCER VACCINES
June 5, 2006
GlaxoSmithKline Plc has signed a deal to licence in a substantial portfolio of tumour-specific antigens from the international
Ludwig Institute for Cancer Research to boost its cancer vaccine portfolio.
The Scotsman
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Jan
-
26Jan
-
27Jan
-
27Jan
-
09Feb
-
10Feb